Abstract:association between long-term diabetes and poor overall survival among patients with diabetes and pancreatic cancer in three longitudinal studies. The authors reported a 40% to 50% increased risk of death for patients with long-term diabetes (duration of 4 years) compared with those without diabetes (P .05) in two prospective cohort studies 2,3 and a clinic-based study. 1 In contrast, no statistically significant association between short-term diabetes (duration of 4 years) and survival was observed. Thus, the authors concluded that there is a link between chronic glucose intolerance and pancreatic cancersurvival,whereasshort-termdiabetesdoesnotportendaworse prognosis among patients with pancreatic adenocarcinoma. We have a concern about the authors’ conclusion regarding the association between short-term diabetes and survival. Because the information on diabetes was collected via a biennial questionnaire in the cohort studies, it is possible that the number of patients with short-term diabetes was greatly underestimated, which may have biased the risk estimate toward null. The prevalence of patients with short-term diabetes was 4.67% (47 of 1,006) and 18.65% (72 of 386), whereas the prevalence of patients with any type of diabetes was 17.99% (181 of 1,006) and 31.35% (121 of 386) in the cohort and the clinic-based studies, respectively. The prevalence of diabetes in the clinic-based study was quite similar to the numbers previously reported by other studies. Short-term diabetes was associated with a nonsignificant but increased risk of death in this clinic series (hazard ratio [HR], 1.22; 95% CI, 0.89 to 1.67). In our recently completed studyof1,328patientswithpathologicallyconfirmedpancreaticductal adenocarcinoma of all stages at MD Anderson Cancer Center, we foundthatshort-termdiabetes(durationof3years)wasassociated with a significantly increased risk of death (HR, 1.23; 95% CI, 1.09 to 1.40).Wehavealsoconductedameta-analysisof29studiesondiabetesandoverallsurvivalofpatientswithpancreaticcancerandfounda reduced survival of patients with diabetes in 25 clinic-based studies (pooled HR, 1.13; 95% CI, 1.02 to 1.25), but not in four cohort studies 4-7 (pooled HR, 1.12; 95% CI, 0.95 to 1.32). The prevalence of patients with diabetes was 28.61% (4,133 of 14,446) and 20.92% (1,124 of 5,372) in the clinic and cohort studies, respectively. These observations suggest that short-term diabetes is associated with a higher risk of death in patients with pancreatic cancer. The inconsistentobservationswithrespecttotheassociationbetweendiabetesand

Insulin-dependence as a Predictor of Shortened Cancer-specific Survival in Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study from the United States Neuroendocrine Study Group

Survival Outcomes and Surgical Intervention of Small Intestinal Neuroendocrine Tumors: a Population Based Retrospective Study

Clinical Significance of the Preoperative Main Pancreatic Duct Dilation and Neutrophil-to-lymphocyte Ratio in Pancreatic Neuroendocrine Tumors (pnets) of the Head after Curative Resection

Impact of Diabetes Mellitus on the Survival of Pancreatic Cancer: a Meta-Analysis

Association of Long-Term, New-Onset, and Postsurgical Diabetes With Survival in Patients With Resectable Pancreatic Cancer

Impact of a Prior Non-Pancreatic Malignancy on Survival Outcomes of Patients with Stage IV Pancreatic Neuroendocrine Tumor: a Population Based and Propensity Score Matching Study

Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors

Diabetes Mellitus and Survival of Non‐small Cell Lung Cancer Patients after Surgery: A Comprehensive Systematic Review and Meta‐analysis

Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis.

Distinct Clinicopathological and Prognostic Features of Insulinoma with Synchronous Distant Metastasis.

The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database

Prognostic Factors of Long-Term Outcome in Surgically Resectable Pancreatic Neuroendocrine Tumors: A 12-Year Experience from A Single Center

Diabetes Associated with Short Survival in Pancreatic Cancer.

P-glycoprotein Associated with Diabetes Mellitus and Survival of Patients with Pancreatic Cancer: 8-Year Follow-Up.

The Role of Diabetes Mellitus in the Malignant Pancreatic Cyst Neoplasm Diagnosis and Prognosis

The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis

Nomograms Predict Survival Outcomes for Distant Metastatic Pancreatic Neuroendocrine Tumor: A Population Based Study

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer

Prognostic Factors and Survival in Patients with Neuroendocrine Tumors of the Pancreas

Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy.